NCT04789252

Brief Summary

Prospective study with the use of biological samples. The centers involved are the Thoracic Surgery and Surgery 1 Units of the San Gerardo Hospital in Monza.

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
64

participants targeted

Target at P25-P50 for all trials

Timeline
Completed

Started Feb 2021

Longer than P75 for all trials

Geographic Reach
1 country

2 active sites

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

February 9, 2021

Completed
8 days until next milestone

First Submitted

Initial submission to the registry

February 17, 2021

Completed
20 days until next milestone

First Posted

Study publicly available on registry

March 9, 2021

Completed
4.9 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

February 9, 2026

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

February 9, 2026

Completed
Last Updated

January 2, 2024

Status Verified

December 1, 2023

Enrollment Period

5 years

First QC Date

February 17, 2021

Last Update Submit

December 29, 2023

Conditions

Keywords

cancerlungcolon cancerdendritic cells

Outcome Measures

Primary Outcomes (2)

  • Single cell bioinformatics analysis RNA-seq

    For the analysis of single-cell RNA-seq data we will exploit the most recent methodologies provided by both 10x Genomics and custom R / Python scripts to perform the identification and characterization of cell subsets.

    Until the end of the study (approximately 5 years).

  • Single cell RNA-seq library preparation and sequencing.

    10,000 cells for each sample will be loaded on an instrument called Chromium 10X (10x genomics).

    Until the end of the study (approximately 5 years).

Secondary Outcomes (2)

  • Spatial distributions of DC subtypes in the tumor microenvironment

    Until the end of the study (approximately 5 years).

  • Correlation between subtypes of myeloid cells present in the tumor microenvironment and survival

    Until the end of the study (approximately 5 years).

Study Arms (1)

Patients with NSCLC or with colon cancer

The subjects are men or women with aged more than 18 years suffering from colon or lung cancer; The lesions are more than 1 cm. They are also able to give informed consent. The pathologist will sample the material and select the tissue that can be used for the experiment after having taken all that is needed for diagnostic purposes. The research sample will be placed in test tubes and kept on ice. It will then be sent to University of Milano-Bicocca laboratory whrere It will analyze approximately 60 patients for immunofluorescence studies and 4 patients for single cell transcriptomic analyzes

Biological: Bioinformatics analysis of single cell transcriptomics data

Interventions

1. Sample collection: Myeloid cell purification + Single cell sequencing 2. Primary analysis: QC sequencing data + Reads alignment + UMI quantification 3. Bioinformatics analysis: Quality Control (Number of genes, UMI content,%mitochondrial genes, % riboprotein genes,Filtering low quality cells) + Normalization and scaling (Normalization, Remove unwanted sources of variation, HVG detection) + PCA Clustering Markers (PCA and PC selection, Clustering, t-SNE, Differential expression for markers identification) 4. Validation: FACS analysis + immunohistochemistry

Patients with NSCLC or with colon cancer

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Patients with NSCLC (primary tumor, adjacent healthy tissue, blood) or colon cancer (primary tumor, normal adjacent tissue, blood)

You may qualify if:

  • men and women aged ≥18 years;
  • clinical diagnosis confirmed by common investigations to establish the presence of colon or lung cancer;
  • lesions\> 1 cm;
  • legal capacity to give informed consent in accordance with ICH / EU GCP and national / local regulations.

You may not qualify if:

  • pregnancy;
  • presumed pregnancy;
  • known coagulation defects;
  • alcohol or drug abuse

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (2)

ASST Monza-C. CHIRURGIA GENERALE E D'URGENZA I

Monza, Italy

NOT YET RECRUITING

ASST Monza-Ospedale San Gerardo, S.C. Chirurgia Toracica

Monza, Italy

RECRUITING

Related Publications (5)

  • Gornati L, Zanoni I, Granucci F. Dendritic Cells in the Cross Hair for the Generation of Tailored Vaccines. Front Immunol. 2018 Jun 27;9:1484. doi: 10.3389/fimmu.2018.01484. eCollection 2018.

    PMID: 29997628BACKGROUND
  • Bottcher JP, Reis e Sousa C. The Role of Type 1 Conventional Dendritic Cells in Cancer Immunity. Trends Cancer. 2018 Nov;4(11):784-792. doi: 10.1016/j.trecan.2018.09.001. Epub 2018 Sep 29.

    PMID: 30352680BACKGROUND
  • Hildner K, Edelson BT, Purtha WE, Diamond M, Matsushita H, Kohyama M, Calderon B, Schraml BU, Unanue ER, Diamond MS, Schreiber RD, Murphy TL, Murphy KM. Batf3 deficiency reveals a critical role for CD8alpha+ dendritic cells in cytotoxic T cell immunity. Science. 2008 Nov 14;322(5904):1097-100. doi: 10.1126/science.1164206.

    PMID: 19008445BACKGROUND
  • Eisenbarth SC. Dendritic cell subsets in T cell programming: location dictates function. Nat Rev Immunol. 2019 Feb;19(2):89-103. doi: 10.1038/s41577-018-0088-1.

    PMID: 30464294BACKGROUND
  • Mingozzi F, Spreafico R, Gorletta T, Cigni C, Di Gioia M, Caccia M, Sironi L, Collini M, Soncini M, Rusconi M, von Andrian UH, Chirico G, Zanoni I, Granucci F. Prolonged contact with dendritic cells turns lymph node-resident NK cells into anti-tumor effectors. EMBO Mol Med. 2016 Sep 1;8(9):1039-51. doi: 10.15252/emmm.201506164. Print 2016 Sep.

    PMID: 27406819BACKGROUND

Biospecimen

Retention: SAMPLES WITH DNA

Samples from patients with NSCLC: primary tumor, adjacent healthy tissue, blood. Samples from patients with colon cancer: primary tumor, normal adjacent tissue, blood.

MeSH Terms

Conditions

Carcinoma, Non-Small-Cell LungNeoplasmsColonic Neoplasms

Condition Hierarchy (Ancestors)

Carcinoma, BronchogenicBronchial NeoplasmsLung NeoplasmsRespiratory Tract NeoplasmsThoracic NeoplasmsNeoplasms by SiteLung DiseasesRespiratory Tract DiseasesColorectal NeoplasmsIntestinal NeoplasmsGastrointestinal NeoplasmsDigestive System NeoplasmsDigestive System DiseasesGastrointestinal DiseasesColonic DiseasesIntestinal Diseases

Central Study Contacts

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

February 17, 2021

First Posted

March 9, 2021

Study Start

February 9, 2021

Primary Completion

February 9, 2026

Study Completion

February 9, 2026

Last Updated

January 2, 2024

Record last verified: 2023-12

Data Sharing

IPD Sharing
Will not share

Locations